Florida Credits a $22.5 Million Grant Program for a 60 Percent Drop in Fentanyl Deaths. The Autopsy Data Can't Say That.

The decline is real and it is large. Florida medical examiners attributed 4,962 deaths to fentanyl in 2023 and about 2,000 in 2025, a fall of nearly 60 percent in two years, and the 2025 annual drug report released Oct. 21 by the Florida Department of Law Enforcement shows the drop continuing rather than stalling.

What is not in that report is any statement about why. Medical examiners count deaths and identify the drugs involved. They do not model causes of trends, and they cannot subtract one program's effect from a dozen simultaneous changes in the drug supply.

Gov. Ron DeSantis, announcing the figures in Orlando on Oct. 20, made the attribution anyway. "Fentanyl-caused deaths in Florida have declined by nearly 60% since we launched the S.A.F.E. grant program in 2023," he said, referring to State Assistance for Fentanyl Eradication, which funds local drug-trafficking investigations. He was joined by Larry Keefe, the FDLE commissioner, and by Sara Carter, director of the Office of National Drug Policy.

The program may well have saved lives. The point is narrower and harder: the evidence presented does not establish it, and the state has not produced the kind of study that could.

Two Years, Two Drops, One Percentage

The 60 percent is not a measurement. It is a multiplication.

Fentanyl-caused deaths fell 35 percent in 2024 and another 37 percent in 2025, according to the medical examiners' series. Compound those two annual rates and you get roughly 59 percent. The headline is the arithmetic consequence of two separate year-over-year declines, presented as a single figure with a single cause.

That matters because the two years are not equivalent. S.A.F.E. was created in 2023, and deaths had already begun falling before it: 5,791 in 2021 at the state's peak, 5,622 in 2022, then 4,962 in 2023. The 2023 decline of about 12 percent predates any plausible effect from a grant program appropriated that same year, when investigations were still being stood up.

DeSantis, asked about the trajectory, offered a forecast rather than a finding: "We have reason to believe that it's falling even more since then."

What the Autopsy Tally Actually Counts

There is a second figure in the report that gets quoted far less often, and the difference between the two is the whole reporting problem.

Florida's examiners distinguish opioid-related deaths — the drug was present in the decedent — from opioid-caused deaths, where the medical examiner concluded after autopsy and toxicology that the drug played a causal role. For 2025 those numbers were 4,094 and 2,494, a gap of 1,600 people who died with opioids in their system but not because of them. In 2024 the same pair read 5,378 and 3,726.

A count built to answer "what killed this person" is being used to answer "did a trafficking grant program work." Those are different questions with different data requirements, and no amount of precision in the first produces an answer to the second.

The Comparison That Doesn't Flatter the Story

Here is where the reporting gets interesting, and where a reader can do work the press release did not.

Florida's total drug-related deaths fell 12 percent from 2024 to 2025. The CDC's provisional estimate for the whole country, covering the 12 months ending March 2026, is a decline of about 12.3 percent. The windows are not identical and the measures are not identical, so this is an approximate comparison rather than a controlled one — but the two figures land almost on top of each other.

Now look at the internal composition of Florida's 2025 report: fentanyl-caused deaths down 37 percent, fentanyl analogs down more than half, opioid-caused deaths down 33 percent, cocaine down 16 percent, methamphetamine down 23 percent, everything down 12 percent.

If a program aimed at fentanyl traffickers were the dominant driver, the sharpest declines should sit where the enforcement landed. Instead the declines are steepest in the fentanyl category and shallower across drug classes with entirely separate supply chains, distribution networks and pharmacology. That pattern is more consistent with a change in what is in the drug supply and how people use it than with the removal of a specific trafficking organization.

Arrests and Pounds Are Output, Not Outcome

The program's own metrics, as released by the governor's office, are these: nearly 3,000 arrests of traffickers and dealers since 2023, more than 600 pounds of fentanyl and 65,000 fentanyl pills seized, 520 pounds of methamphetamine, nearly 1,000 firearms and 90 vehicles.

The Legislature appropriated more than $22.5 million for S.A.F.E. in the 2026-27 fiscal year, and the program has run since 2023. Note what that combination does and does not permit: because the arrest count is cumulative across roughly three years while the budget figure covers one, a per-arrest cost cannot honestly be derived from the two numbers together. Anyone quoting one is guessing at the other years' appropriations.

The deeper issue is category. Arrests, pounds and firearms measure whether police did things. They do not measure deaths avoided, and a program can produce impressive totals in the first category while having no detectable effect on the second. The counterfactual that would settle it — how many deaths would Florida have recorded without S.A.F.E. — is unobservable in principle without a comparison design, and no such design has been published.

What a Real Evaluation Would Look Like

It is not exotic. Florida has 25 medical examiner districts that do not all run the same enforcement intensity, and the annual report already breaks deaths out geographically. A district-level difference-in-differences design, comparing districts with heavy S.A.F.E. grant participation against comparable districts without it, would take one analyst and the data the state already holds. That the report is published by district and the evaluation has not been done is the most concrete criticism available.

The Researchers Who Study This Point Elsewhere

When Florida's overdose deaths first showed a sharp decline in the first half of 2025, Claire Zagorski, a University of Texas at Austin researcher who studies drug supply trends, told WUWF there was no compelling evidence the fall was due to law enforcement.

Tim Santamour, executive director of the Florida Harm Reduction Collective, offered a mechanism instead: sedatives such as xylazine and medetomidine displacing high-dose fentanyl in the supply, a shift from injecting to smoking, and wider use of fentanyl test strips and naloxone.

That account fits the data better than it first appears. A supply where fentanyl is cut with non-opioid sedatives kills fewer people per dose of opioid but produces more weird, prolonged sedations that naloxone does not reverse — which shows up as fewer fentanyl-caused deaths and a stubborn residual of total drug mortality, exactly the -37 and -12 split in the report.

None of this clears the traffickers or proves the program useless. It establishes only that several changes happened at once, that the available data cannot rank them, and that the state has chosen the most flattering ranking without testing it.

What Remains True Regardless

Fentanyl still caused about 2,000 deaths in Florida in 2025 — more than any other drug, and roughly the population of a small town. Counterfeit pills bought outside a pharmacy still contain it. People returning to use after a break still overdose at high rates because tolerance falls faster than habit does.

And the sedative shift creates a specific hazard that the enforcement framing obscures. Naloxone reverses opioids; it does not reverse xylazine or medetomidine. A person can be revived and still be unresponsive, which means the instruction to call 911 and stay has become more important, not less. Fentanyl test strips have been legal in Florida since July 2023, and opioid addiction treatment with buprenorphine or methadone remains the intervention with the strongest evidence base for keeping people alive across years rather than hours.

The honest version of the governor's announcement would read: fentanyl deaths in Florida have fallen almost 60 percent in two years, in line with a national decline and faster within the fentanyl category specifically, for reasons that are probably a mix of supply change, expanded naloxone, treatment growth and enforcement, in proportions nobody has measured. That sentence is less quotable. It is also the one the data support.

For families trying to act on any of it, the useful facts are unglamorous. Keep naloxone at home; it is sold over the counter. Know that a revived person may still need an ambulance. Do not read a falling statewide death count as evidence that the local supply has gotten safer, because medication-assisted treatment referrals and 911 calls are still decided one household at a time.